Serum vitamin D concentration and prostate cancer risk: a nested case-control study.

BACKGROUND Epidemiological studies have yielded inconsistent associations between vitamin D status and prostate cancer risk, and few studies have evaluated whether the associations vary by disease aggressiveness. We investigated the association between vitamin D status, as determined by serum 25-hydroxyvitamin D [25(OH)D] level, and risk of prostate cancer in a case-control study nested within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. METHODS The study included 749 case patients with incident prostate cancer who were diagnosed 1-8 years after blood draw and 781 control subjects who were frequency matched by age at cohort entry, time since initial screening, and calendar year of cohort entry. All study participants were selected from the trial screening arm (which includes annual standardized prostate cancer screening). Conditional logistic regression was used to estimate adjusted odds ratios (ORs) with 95% confidence intervals (CIs) by quintile of season-standardized serum 25(OH)D concentration. Statistical tests were two-sided. RESULTS No statistically significant trend in overall prostate cancer risk was observed with increasing season-standardized serum 25(OH)D level. However, serum 25(OH)D concentrations greater than the lowest quintile (Q1) were associated with increased risk of aggressive (Gleason sum > or = 7 or clinical stage III or IV) disease (in a model adjusting for matching factors, study center, and history of diabetes, ORs for Q2 vs Q1 = 1.20, 95% CI = 0.80 to 1.81, for Q3 vs Q1 =1.96, 95% CI = 1.34 to 2.87, for Q4 vs Q1 = 1.61, 95% CI = 1.09 to 2.38, and for Q5 vs Q1 = 1.37, 95% CI = 0.92 to 2.05; P(trend) = .05). The rates of aggressive prostate cancer for increasing quintiles of serum 25(OH)D were 406, 479, 780, 633, and 544 per 100 000 person-years. In exploratory analyses, these associations with aggressive disease were consistent across subgroups defined by age, family history of prostate cancer, diabetes, body mass index, vigorous physical activity, calcium intake, study center, season of blood collection, and assay batch. CONCLUSION The findings of this large prospective study do not support the hypothesis that vitamin D is associated with decreased risk of prostate cancer; indeed, higher circulating 25(OH)D concentrations may be associated with increased risk of aggressive disease.

[1]  Yan Liu,et al.  Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. , 2006, Journal of the National Cancer Institute.

[2]  D. Spiegelman,et al.  Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25‐hydroxyvitamin D and 1,25‐dihydroxyvitamin D, and prostate cancer risk , 2007, The Prostate.

[3]  G. Schwartz,et al.  Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation , 1992, Cancer.

[4]  B. Hollis,et al.  Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioiodinated tracers. , 1997, Methods in enzymology.

[5]  E. Corder,et al.  Vitamin D and prostate cancer: a prediagnostic study with stored sera. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  Pär Stattin,et al.  Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case‐control study in the Nordic countries , 2004, International journal of cancer.

[7]  E. Jacobs,et al.  Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  H. DeLuca,et al.  Mechanisms and functions of vitamin D. , 2009, Nutrition reviews.

[9]  Paul S Albert,et al.  Using lowess to remove systematic trends over time in predictor variables prior to logistic regression with quantile categories , 2003, Statistics in medicine.

[10]  John H. White,et al.  The pleiotropic actions of vitamin D. , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[11]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[12]  E. Giovannucci,et al.  Plasma 1,25-Dihydroxy- and 25-Hydroxyvitamin D and Subsequent Risk of Prostate Cancer , 2004, Cancer Causes & Control.

[13]  M. Graffar.  [Modern epidemiology]. , 1971, Bruxelles medical.

[14]  Ruth Etzioni,et al.  Associations of demographic and lifestyle characteristics with prostate‐specific antigen (PSA) concentration and rate of PSA increase , 2006, Cancer.

[15]  T. Stamey,et al.  Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. , 1994, Cancer research.

[16]  J. Michael Gaziano,et al.  A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer , 2007, PLoS medicine.

[17]  D. Albanes,et al.  A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. , 2006, Cancer research.

[18]  E. John,et al.  Residential sunlight exposure is associated with a decreased risk of prostate cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  C. Abnet,et al.  Serum 25(OH)-Vitamin D Concentration and Risk of Esophageal Squamous Dysplasia , 2007, Cancer Epidemiology Biomarkers & Prevention.

[20]  S. Ingles,et al.  Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. , 2005, Cancer research.

[21]  P C Prorok,et al.  Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.

[22]  M. Hakama,et al.  Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland) , 2000, Cancer Causes & Control.

[23]  D. Peehl,et al.  Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. , 1993, Endocrinology.

[24]  R. Mason,et al.  Stability of vitamin D metabolites in human blood serum and plasma. , 1981, Clinical chemistry.

[25]  R. Strange,et al.  Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer , 2001, The Lancet.

[26]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[27]  C. Abnet,et al.  Prospective study of serum 25(OH)-vitamin D concentration and risk of oesophageal and gastric cancers , 2007, British Journal of Cancer.

[28]  Robert N Hoover,et al.  Methods for etiologic and early marker investigations in the PLCO trial. , 2005, Mutation research.

[29]  G. Oades,et al.  Vitamin D receptor‐dependent antitumour effects of 1,25‐dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer , 2002, BJU international.

[30]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[31]  L. Kolonel,et al.  Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States) , 1998, Cancer Causes & Control.

[32]  A F Subar,et al.  Evaluation of alternative approaches to assign nutrient values to food groups in food frequency questionnaires. , 2000, American journal of epidemiology.

[33]  M. Stampfer,et al.  Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.